Status:

COMPLETED

Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke

Lead Sponsor:

MetroHealth Medical Center

Collaborating Sponsors:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Case Western Reserve University

Conditions:

Stroke

Hemiparesis

Eligibility:

All Genders

21-75 years

Phase:

NA

Brief Summary

This is a small pilot randomized controlled trial which will enroll both subacute (\<6 mos) and chronic (\>6 mos) stroke survivors with ankle dorsiflexion weakness. The subjects will be randomized to ...

Eligibility Criteria

Inclusion

  • Age 21 to 75 years
  • Minimum of 2 wks from a first clinical non-hemorrhagic or hemorrhagic stroke
  • Medically stable
  • Unilateral lower extremity hemiparesis
  • Ankle dorsiflexor strength of ≤4/5 on the Medical Research Council scale, while seated
  • NMES of the paretic ankle dorsiflexors produces ankle dorsiflexion to neutral without pain.
  • Full voluntary ROM of the contralateral ankle
  • Skin intact on bilateral lower extremities
  • Able to don the NMES system or caregiver available to assist with device if needed.
  • Able to hear and respond to stimulator auditory cues
  • Able to follow 3-stage commands
  • Able to recall 2 of 3 items after 30 minutes
  • Cognition and communication adequate for safe use of the device based on neurological assessment by physician principal investigator

Exclusion

  • Severely impaired cognition and communication
  • History of peroneal nerve injury
  • History of Parkinson's, spinal cord injury, traumatic brain injury, or multiple sclerosis
  • Uncontrolled seizure disorder
  • Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)
  • Edema of the paretic lower extremity
  • Absent sensation of paretic lower extremity
  • Evidence of deep venous thrombosis or thromboembolism
  • History of cardiac arrhythmias with hemodynamic instability
  • Cardiac pacemaker or other implanted electronic system
  • Botulinum toxin injections to any lower extremity muscle in the last 3 months
  • Pregnancy
  • Symptomatic peripheral neuropathy
  • Current use of psychoactive medications (except selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor antidepressants)
  • Acetylcholinesterase inhibitor usage
  • Unstable asthmatic condition
  • Metallic implants (including clips and/or wires)
  • Prosthetic heart valves
  • Cardiac, renal or other stent
  • History of claustrophobia
  • Low visual acuity
  • Body weight or body habitus not compatible to MRI machine
  • Medical, psychological, or social concern identified by the principal investigator or co-investigator which suggests inappropriateness of subject participation

Key Trial Info

Start Date :

May 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2015

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT02199795

Start Date

May 1 2014

End Date

February 1 2015

Last Update

November 8 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

MetroHealth Medical Center

Cleveland, Ohio, United States, 44109